Dell Technologies Inc. (NYSE: DELL): What EMC’s $984.3 m Air Force award means for defense IT strategy
Read More Pharma Industry News Lyra Therapeutics reports disappointing results for LYR-210 in Phase 3 chronic rhinosinusitis trial Lyra Therapeutics, Inc. (Nasdaq: LYRA), dedicated to advancing treatments for chronic rhinosinusitis (CRS), announced that its Phase 3… byPallavi MadhirajuMay 7, 2024